Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

Patients with psoriatic arthritis (PsA) have delays in diagnosis compared with those with rheumatoid arthritis (RA).

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) ...

Oral opioid use is common among patients with SPRA, ankylosing spondylitis, and PsA and is associated with an increased risk of mortality.

AbbVie Inc.'s Q1 earnings highlight an 8.4% revenue boost, driven by Skyrizi & Rinvoq. Click for ABBV's market expansion, ...

Celltrion, Inc. announced that the U.S. Food and Drug Administration granted an interchangeable designation to ...

Psoriatic arthritis combines painful joint inflammation ... the spine becomes involved in what’s known as psoriatic spondylitis. This manifestation causes inflammation in the spinal joints ...

FRIDAY, April 18, 2025 (HealthDay News) -- It’s taking too long for people with psoriatic arthritis to be diagnosed and treated, a new study argues. Visible signs of psoriatic arthritis appear ...

Psoriatic arthritis represents one of the more challenging inflammatory conditions in rheumatology, affecting approximately 20% of individuals with psoriasis while sometimes developing ...